Results 181 to 190 of about 32,827 (233)

DIRAS1 Drives Oxaliplatin Resistance in Colorectal Cancer via PHB1-Mediated Mitochondrial Homeostasis. [PDF]

Biology (Basel)
Long M, Ouyang Q, Wen J, Zeng X, Xu Z, Zhong S, Huang C, Luo JL.   +7 more
europepmc   +1 more source

A Novel Combination Therapy for Human Oxaliplatin-resistant Colorectal Cancer using Oxaliplatin and Coxsackievirus A11

A Novel Combination Therapy for Human Oxaliplatin-resistant Colorectal Cancer using Oxaliplatin and Coxsackievirus A11
Background: Colorectal cancer (CRC) is a major cause of morbidity and mortality throughout the world. It is the third most common cancer worldwide and the fourth most common cause of cancer-related death. FOLFOX, a combination of leucovorin calcium, fluorouracil, and oxaliplatin, is the first-line chemotherapy for stage III and stage IV CRC.
openaire  

DEPP1: A prognostic biomarker linked to stroma‑rich and immunosuppressive microenvironment, promoting oxaliplatin resistance in gastric cancer. [PDF]

Oncol Rep
Qiu X, Pan T, Kuang T, Shen Y, Zheng Y, Geng H, Ni B, Xia X, Zhu C, Zhang Z, Cao H, Tu L.   +11 more
europepmc   +1 more source

Research Progress on Reversing Oxaliplatin Resistance in Colon Cancer

Advances in Clinical Medicine, 2023
openaire   +1 more source

Alectinib and SALL4-Targeted Fatty Acid Oxidation: A Strategy to Combat Oxaliplatin Resistance in Gastric Cancer. [PDF]

Turk J Gastroenterol
Xiao Y, Fang K, Liao J, Zhou H, Zhu W, Liu Z, Ouyang H, Liu K.   +7 more
europepmc   +1 more source

NAD+/SIRT1 pathway regulates glycolysis to promote oxaliplatin resistance in colorectal cancer. [PDF]

World J Gastroenterol
Niu YR, Xiang MD, Yang WW, Fang YT, Qian HL, Sun YK.   +5 more
europepmc   +1 more source

RETRACTION: LncRNA NR2F1-AS1 Regulates Hepatocellular Carcinoma Oxaliplatin Resistance by Targeting ABCC1 via miR-363. [PDF]

J Cell Mol Med
europepmc   +1 more source

Increased keratin 80 expression predicts poor prognosis and promotes oxaliplatin resistance in gastric cancer. [PDF]

World J Gastroenterol
Yang B, Cao HX, He YW, Ouyang JJ, Lv M, Li YX, Lu YD.   +6 more
europepmc   +1 more source

Modeling oxaliplatin resistance in colorectal cancer reveals a SERPINE1-based gene signature (RESIST-M) and therapeutic strategies for pro-metastatic CMS4 subtype. [PDF]

Cell Death Dis
Wong SQR, Das M, Tenzin K, Shirgaonkar N, Chua H, Chee LX, Sae Yeoh A, Murugiah AA, Chua WY, Theardy MS, Subel EJ, Thangavelu MT, Chan JV, Yap CK, Tan IBH, Tsantoulis P, Tejpar S, Loo JM, DasGupta R.   +18 more
europepmc   +1 more source

Correction: THBS2 + cancer-associated fibroblasts promote EMT leading to oxaliplatin resistance via COL8A1-mediated PI3K/AKT activation in colorectal cancer. [PDF]

Mol Cancer
Zhou X, Han J, Zuo A, Ba Y, Liu S, Xu H, Zhang Y, Weng S, Zhou Z, Liu L, Luo P, Cheng Q, Zhang C, Chen Y, Shan D, Liu B, Yang S, Han X, Deng J, Liu Z.   +19 more
europepmc   +1 more source